Embecta (EMBC) vs InfuSystems (INFU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InfuSystems (INFU) has outperformed Embecta (EMBC) over the past year, gaining 36.6% versus a loss of 58.4%. Embecta is the larger company by market cap ($329.5 million vs $271.4 million), about 1.2 times the size. On valuation, Embecta trades at a lower forward P/E (3.3x vs 26.2x for InfuSystems).
Embecta pays a dividend yielding 7.91%, while InfuSystems does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | INFU |
|---|---|---|
| Share price | $5.82 | $13.63 |
| Market cap | $329.48M | $271.37M |
| 1-day change | +1.13% | +1.60% |
| YTD return | -51.60% | +49.50% |
| 1-year return | -58.39% | +36.56% |
| 5-year return | — | +4.20% |
| P/E ratio (TTM) | 3.96 | 34.06 |
| Forward P/E | 3.30 | 26.20 |
| EPS (TTM) | $1.47 | $0.40 |
| Dividend yield | 7.91% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| 52-week high | $14.91 | $13.85 |
| 52-week low | $2.77 | $7.29 |
| Distance from 52-week high | -61.00% | -1.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -31.21% | +23.52% |
| Average volume | 1.37M | 140.07K |
| Shares outstanding | 56.66M | 19.92M |
| Employees | 1,850 | 461 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed EMBC by 95.0 percentage points over the past year.
- InfuSystems trades at a higher earnings multiple (34.1x vs 4.0x trailing P/E).
- Embecta offers a meaningfully higher dividend yield (7.91% vs 0.00%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
EMBC vs INFU FAQ
Which is bigger, Embecta or InfuSystems?
Embecta (EMBC) is larger, with a market capitalization of $329.48M compared with $271.37M for InfuSystems (INFU).
Which stock has performed better over the past year, EMBC or INFU?
INFU returned +36.56% over the past 12 months, compared with -58.39% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EMBC or INFU?
EMBC has the lower trailing P/E at 4.0, versus 34.1 for INFU. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Embecta or InfuSystems?
Embecta pays a dividend yielding 7.91%, while InfuSystems does not currently pay a regular dividend.
Are Embecta and InfuSystems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.